Free tool
FAERS Monitor: Lysteda
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022430 or its brand name (Lysteda, Tranexamic Acid). Reports on generic versions are filed under their own applications.
Reports
8,563
Serious
7,950
93% of reports
Hospitalization
3,859
Death reported
1,245
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective641
- off label use632
- pyrexia347
- hypotension322
- nausea322
- diarrhoea308
- haemorrhage296
- vomiting290
- dyspnoea283
- pneumonia265
- febrile neutropenia246
- anaphylactic reaction230
- headache229
- anaemia222
- seizure217
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 37 |
| 2005 | 33 |
| 2006 | 39 |
| 2007 | 31 |
| 2008 | 65 |
| 2009 | 62 |
| 2010 | 144 |
| 2011 | 181 |
| 2012 | 164 |
| 2013 | 161 |
| 2014 | 173 |
| 2015 | 263 |
| 2016 | 296 |
| 2017 | 385 |
| 2018 | 445 |
| 2019 | 632 |
| 2020 | 579 |
| 2021 | 806 |
| 2022 | 843 |
| 2023 | 675 |
| 2024 | 917 |
| 2025 | 997 |
| 2026 | 635 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,596 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anaphylactic reactionSignal | 230 | 10.3 | 9.0 | 1,911 |
| febrile neutropeniaSignal | 246 | 9.1 | 8.1 | 1,774 |
| haemorrhageSignal | 296 | 7.0 | 6.2 | 1,512 |
| seizureSignal | 217 | 4.6 | 4.1 | 614 |
| hypotensionSignal | 322 | 3.9 | 3.5 | 711 |
| anaemiaSignal | 222 | 2.9 | 2.5 | 269 |
| pyrexiaSignal | 347 | 2.5 | 2.2 | 305 |
| pneumoniaSignal | 265 | 2.0 | 1.8 | 136 |
| off label use | 632 | 1.8 | 1.6 | 221 |
| vomiting | 290 | 1.5 | 1.4 | 51 |
| dyspnoea | 283 | 1.2 | 1.1 | 12 |
| drug ineffective | 641 | 1.2 | 1.1 | 21 |
| diarrhoea | 308 | 1.2 | 1.1 | 8 |
| nausea | 322 | 1.0 | 0.9 | 0 |
| headache | 229 | 0.9 | 0.8 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.